Menu
Menu
SOPHiA GENETICS is thrilled to return and join the genomics community at this year’s American Society of Human Genetics (ASHG) Annual Meeting in Boston, Massachusetts.
Visit Booth #1040 to explore the next-generation SOPHiA DDM™ Platform and Alamut™ Visual Plus, and uncover our latest advancements in Enhanced Exome and Whole Genome Sequencing analytics.
Join us and be part of the conversation with our experts, partners, and users as we tackle the challenges of rare and inherited disorder and pharmacogenomic analysis.
Poster Presentation
Wednesday, Oct 15 | 02:30 – 04:30 PM | Exhibit & Poster Hall, Lower Level Board 8008W
Authored and presented by: Adrian Janiszewski
Co-lab Theater Talk
Thursday, Oct 16 | 12:00 – 12:30 pm | Theatre 1, Exhibit & Poster Hall, Lower Level
Simple workflows for complex genomics: A closer look at our latest enhanced exome and whole genome capabilities
Presented by: Guilherme Yamamoto, Head of Genomics and Bioinformatics Innovation, Dasa Brazil
Presented by: Izabela Matyszczak, Technical Product Management Expert, Genomic Research Expert, SOPHiA GENETICS
Speaker:
Cristovam Scapulatempo Neto, MD, PhD - Medical Director of Pathology and Genetics, Diagnósticos da América S.A.
Comprehensive genomic profiling (CGP) is transforming precision oncology by enabling more precise and personalized cancer care. However, as demand for testing grows, many clinical laboratories face significant operational hurdles—from fragmented and rigid analysis workflows to long turnaround times. Decentralized testing enables laboratories to perform large-scale molecular analysis in-house, retain full control of their data, and streamline workflows to accelerate time to results.
In this Inside Precision Medicine webinar, Cristovam Scapulatempo Neto, MD, PhD, will explore how a decentralized, tech-agnostic approach can help laboratories expand their CGP capabilities. Using SOPHiA DDM™ for CGP by SOPHiA GENETICS as an example, he will discuss how this advanced analytical solution, which is designed to be compatible with a wide range of sequencing platforms, helps laboratories streamline processes and scale testing without compromising accuracy. The webinar will provide insights into what the solution offers, including:
Join us for a live webinar hosted by Nature Research, AI in Genomics: Enhancing Germline Workflows to Tackle the Biggest Research Challenges, where leading experts will explore how AI-powered solutions are reshaping variant analysis and driving breakthroughs in precision medicine.
This webcast will explore how to unlock the potential of germline research with cutting-edge advancements in AI-powered workflows, highlighting the New Generation SOPHiA DDM™ Platform.
What You’ll Learn
✅ Cutting-edge AI applications for germline research
✅ Strategies to improve data accuracy, scalability, and speed
✅ Real-world case studies of AI-driven workflows solving complex research challenges
We are thrilled to announce our participation in the ESMO Asia Congress 2024!
Join the SOPHiA GENETICS team at booth #E406 and explore how we are driving groundbreaking innovations in cancer research and treatment.
From our collaboration with Memorial Sloan Kettering cancer Center to decentralize MSK-ACCESS and MSK-IMPACT, to our launch of SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution, we are committed to supporting clinical researchers with variant detection and analysis, biomarker discovery, and therapy selection.
We look forward to connecting with you at ESMO Asia 2024!
SOPHiA GENETICS™ is excited to be a part of the American Association for Cancer Research annual meeting, held in person in Orlando, FL from April 14th-19th.
You will have the chance to chat with our experts at booth #123 and learn how our BioPharma solutions may be right for you.
Decentralization and Collective Intelligence: Pioneering a New Era in Precision Medicine
Sunday, April 16
1:30 - 2:30 pm
Exhibitor Spotlight Theatre E
Join us on a journey to revolutionize clinical research programs with decentralized collective intelligence. See decentralization in motion with the SOPHiA DDM™ Platform, designed to connect and integrate multimodal data from 750+ institutions across 70 countries. Learn how to unlock the platform’s potential to identify unmet needs, accelerate precision medicine development, and improve patient access to new therapies by securely sharing knowledge on a global scale. Discover how SOPHiA DDM™ continues to drive and accelerate the adoption of homologous recombination deficiency (HRD) analysis and our decentralized approach to MSK-ACCESS®.
Presented by: T. Scott Reid, PhD - VP, Global Head of Diagnostics
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.